Literature DB >> 2417478

Primary Sjögren's syndrome in men. Clinical, serologic, and immunogenetic features.

R Molina, T T Provost, F C Arnett, W B Bias, M C Hochberg, R W Wilson, E L Alexander.   

Abstract

Although primary Sjögren's syndrome is a common rheumatic disorder in women, it is not well recognized in men. This study represents the first report of the clinical, serologic, and immunogenetic features of a group of 36 men with primary Sjögren's syndrome, which are contrasted with those of a group of 69 women with primary Sjögren's syndrome. The majority of male patients had extraglandular involvement including articular (78 percent), neurologic (39 percent), inflammatory vascular (25 percent), and lymphoproliferative disorders (17 percent). Although men were at the same risk for the development of extraglandular complications, there were significant serologic and immunogenetic differences. In sharp contrast to women with Sjögren's syndrome, men with Sjögren's syndrome were seronegative with respect to the presence of serum rheumatoid factor (p = 0.008) and antibodies to Ro(SS-A) (p = 0.016). The supertypic specificity, MT2 (DRw52), as in women, was strongly associated with primary Sjögren's syndrome in men when compared with race-matched control subjects (p = 0.0015). In men, however, the frequency of HLA-B8 and HLA-DR3, the most common DR locus specificity observed in women, was not statistically different from that observed in the normal control group.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2417478     DOI: 10.1016/0002-9343(86)90044-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

1.  Primary Sjögren's syndrome from the viewpoint of an internal physician.

Authors:  G Pokorny; J Németh; I Marczinovits; M Kiss; J Hudák; S Husz
Journal:  Int Ophthalmol       Date:  1991-11       Impact factor: 2.031

2.  Unusual presentation of Sjögren's syndrome.

Authors:  Aicha Bouraoui; Syed Farhan Bari; Julian Nash; Kenneth Dawson
Journal:  BMJ Case Rep       Date:  2014-11-20

3.  Nervous system disease, immunological features, and HLA phenotype in Sjögren's syndrome.

Authors:  A Hietaharju; M Korpela; J Ilonen; H Frey
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

Review 4.  Genetics of Sjögren's syndrome.

Authors:  Leyla Y Teos; Ilias Alevizos
Journal:  Clin Immunol       Date:  2017-05-03       Impact factor: 3.969

5.  A case of primary Sjögren's syndrome complicated with inflammatory myopathy and interstitial lung disease.

Authors:  Tomohiro Koga; Yukiko Kouhisa; Hideki Nakamura; Akinari Mizokami; Masakatsu Motomura; Atsushi Kawakami; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2010-05-12       Impact factor: 2.631

6.  Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome.

Authors:  V Goëb; V Salle; P Duhaut; F Jouen; A Smail; J-P Ducroix; F Tron; X Le Loët; O Vittecoq
Journal:  Clin Exp Immunol       Date:  2007-02-07       Impact factor: 4.330

7.  Gender differences in patients with chronic fatigue syndrome.

Authors:  D Buchwald; T Pearlman; P Kith; K Schmaling
Journal:  J Gen Intern Med       Date:  1994-07       Impact factor: 5.128

8.  HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody responses to nuclear antigens.

Authors:  J S Smolen; J H Klippel; E Penner; M Reichlin; A D Steinberg; T M Chused; O Scherak; W Graninger; E Hartter; C C Zielinski
Journal:  Ann Rheum Dis       Date:  1987-06       Impact factor: 19.103

9.  HLA-DR4 and Gm(1,3;5,21) are associated with U1-nRNP antibody positive connective tissue disease.

Authors:  E Genth; H Zarnowski; R Mierau; D Wohltmann; P W Hartl
Journal:  Ann Rheum Dis       Date:  1987-03       Impact factor: 19.103

10.  Primary Sjögren's syndrome in men: clinical and immunological characteristic based on a large cohort of Hungarian patients.

Authors:  Ildiko Fanny Horvath; Peter Szodoray; Margit Zeher
Journal:  Clin Rheumatol       Date:  2008-06-14       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.